Compare Honeywell International Inc (HON) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Mesoblast Limited — how do they compare? Honeywell International Inc trades at $207 (market cap $65.96B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Honeywell International Inc is far larger — about 36.4× Mesoblast Limited's market cap, and Honeywell International Inc pays a 1.35% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Mesoblast Limited for 14 Days on average.
| HON | MESO | |
|---|---|---|
Market Cap | $65.96B | $1.81B |
Volume | 2,009,898 | 240,620 |
Sector | Industrials | Health |
52-Week High | $248.79 | $20.96 |
52-Week Low | $188.14 | $13.19 |
Typical Hold Time | 90 Days | 14 Days |
Enterprise Value | $90.75B | $1.89B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $206.6, down 2.95% on the day, with a bearish technical signal despite strong fundamentals including a low P/E of 8 and robust profitability margins. Recent quarterly earnings have consistently beaten expectations, and the company secured a significant $300 million refinery project with Dangote. Analyst consensus remains strongly bullish with a $259.25 price target, representing 25% upside potential from current levels.
The stock presents a compelling value opportunity given its discounted valuation metrics and consistent earnings outperformance, though investors face near-term technical headwinds and execution risks from the company's recent strategic transformation into a pure-play automation business following the spin-off of its aerospace and advanced materials divisions.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
